SCHEMBL5484218

SCHEMBL5484218

Cc1cc(Cl)cc2c1NC(=O)C2(c1ccc(NS(C)(=O)=O)cc1)c1ccc(NS(C)(=O)=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.42
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KCNH2 Q12809 1/20 0.41
HTT P42858 2/20 0.41
CNR1 P21554 1/20 0.41
GPR35 Q9HC97 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
CES1 P23141 1/20 0.40
TDP2 O95551 1/20 0.36
PTGS2 P35354 1/20 0.36
PGR P06401 1/20 0.36
MET P08581 1/20 0.36
CYP17A1 P05093 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5479295 0.84 KIF11 (0.40) KIF11SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL5488536 0.81 SMN1; SMN2 (0.55) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL5486000 0.80 CNR1 (0.63) KCNH2HTTCNR1GPR35GPR55
SCHEMBL5485549 0.79 KIF11 (0.40) KIF11KCNH2HTTCNR1GPR35
SCHEMBL5482571 0.73 KIF11 (0.40) KIF11SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL5474271 0.73 KIF11 (0.40) KIF11KCNH2HTTTDP2PGR
SCHEMBL5478650 0.73 KIF11 (0.38) KIF11KCNH2HTTCNR1GPR35
SCHEMBL5482098 0.72 HTT (0.39) KIF11HTTCNR1GPR35GPR55
SCHEMBL5482310 0.71 SMN1; SMN2 (0.38) KIF11HTTTDP2PGRSMN1; SMN2
SCHEMBL5480073 0.70 MET (0.44) KCNH2HTTCNR1GPR35GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 KIF11 4188/4885SLC6A2 4672/4885SLC6A4 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.